{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:06:04Z","timestamp":1788332764545,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.coph.2021.11.003","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T07:13:38Z","timestamp":1638947618000},"page":"23-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Emerging drugs for the treatment of primary sclerosing cholangitis"],"prefix":"10.1016","volume":"62","author":[{"given":"Nadir","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Nabil","family":"Quraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.11.003_bib1","first-page":"CD011343","article-title":"Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis","volume":"3","author":"Saffioti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.11.003_bib2","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib3","series-title":"Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","year":"2018"},{"key":"10.1016\/j.coph.2021.11.003_bib4","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","author":"Trivedi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib5","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"de Vries","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.coph.2021.11.003_bib6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","article-title":"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis","volume":"34","author":"Imam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015081","article-title":"Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): a single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol","volume":"7","author":"Arndtz","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.coph.2021.11.003_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib11","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coph.2021.11.003_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib13","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2036.2011.04658.x","article-title":"Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis","volume":"33","author":"Culver","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib15","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coph.2021.11.003_bib16","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coph.2021.11.003_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib19","series-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis - trauner","year":"2017"},{"key":"10.1016\/j.coph.2021.11.003_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib21","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib22","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.22891","article-title":"Side chain structure determines unique physiologic and therapeutic properties of norUrsodeoxycholic acid in Mdr2\u2212\/\u2212 mice","volume":"49","author":"Halilbasic","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"9","author":"Trivedi","year":"2016","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.coph.2021.11.003_bib24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and indirect effects of fibroblast growth factor (FGF) 15 and FGF19 on liver fibrosis development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib25","first-page":"3","article-title":"The pharmacology of bile acids and their receptors","volume":"vol. 256","author":"Fiorucci","year":"2019"},{"key":"10.1016\/j.coph.2021.11.003_bib26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.11.003_bib28","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.11.003_bib29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coph.2021.11.003_bib30","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib31","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/hq1101.098228","article-title":"Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression","volume":"21","author":"Post","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coph.2021.11.003_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11901-019-00454-4","article-title":"Future medical treatment of PSC","volume":"18","author":"Krones","year":"2019","journal-title":"Curr Hepat Rep"},{"key":"10.1016\/j.coph.2021.11.003_bib33","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.11.003_bib34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00535-010-0204-x","article-title":"Bezafibrate for the treatment of primary sclerosing cholangitis","volume":"45","author":"Mizuno","year":"2010","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jhbp.281","article-title":"Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis","volume":"22","author":"Mizuno","year":"2015","journal-title":"J\u00a0Hepato-Biliary-Pancreatic Sci"},{"key":"10.1016\/j.coph.2021.11.003_bib37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1185\/030079902125000516","article-title":"Effects of fibrates on serum metabolic parameters","volume":"18","author":"Elisaf","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.coph.2021.11.003_bib39","first-page":"S426","article-title":"Real world experience of second line treatments: UK experience. Oral presentation presented at: International liver congress 2021","volume":"75","author":"Abbas","year":"2021","journal-title":"Int Liver Congr"},{"key":"10.1016\/j.coph.2021.11.003_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Ileal bile acid transporter inhibitor GSK2330672 improves pruritus in primary biliary cholangitis: a double blind, randomised, placebo-controlled, crossover, phase IIa study","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.11.003_bib41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A\u00a0randomized, controlled, phase 2 study of Maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.coph.2021.11.003_bib42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.28274","article-title":"Integrin \u03b1v\u03b26 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis","volume":"63","author":"Peng","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib43","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","article-title":"Inhibition of integrin Alphavbeta6 on cholangiocytes blocks tgfbeta activation and retards biliary fibrosis progression","volume":"135","author":"Patsenker","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib44","article-title":"A\u00a0blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage","volume":"2","author":"Segal-Salto","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.coph.2021.11.003_bib45","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/S0168-8278(20)31452-5","article-title":"FRI174 - CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2\u2013\/\u2013 mouse model","volume":"73","author":"Barashi","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2013.06.013","article-title":"Mucosal immunity in liver autoimmunity: a comprehensive review","volume":"46","author":"Trivedi","year":"2013","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.coph.2021.11.003_bib47","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.12.002","article-title":"Gut - liver immunity","volume":"64","author":"Trivedi","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib48","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib49","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/gutjnl-2016-311915","article-title":"The gut-adherent microbiota of PSC-IBD is distinct to that of IBD","volume":"66","author":"Quraishi","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis","volume":"50","author":"R\u00fchlemann","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib52","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/ecco-jcc\/jjaa021","article-title":"A\u00a0pilot integrative analysis of colonic gene expression, gut microbiota, and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways","volume":"14","author":"Quraishi","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.coph.2021.11.003_bib53","article-title":"Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis","author":"Kummen","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/ecco-jcc\/jjv204","article-title":"Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis","volume":"10","author":"Kevans","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.coph.2021.11.003_bib55","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/apt.13552","article-title":"The features of mucosa-associated microbiota in primary sclerosing cholangitis","volume":"43","author":"Torres","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib56","article-title":"Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis","author":"Lemoinne","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib57","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A\u00a0triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J\u00a0Gastrointest Liver Dis JGLD"},{"key":"10.1016\/j.coph.2021.11.003_bib59","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"Ali","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib60","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis\u2013ulcerative colitis","volume":"68","author":"Tan","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib61","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/ibd\/izz027","article-title":"Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary sclerosing cholangitis","volume":"25","author":"Dao","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2021.11.003_bib62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","article-title":"Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic","volume":"47","author":"Davies","year":"2008","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.coph.2021.11.003_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhin.2018.06.024","article-title":"Point-prevalence survey of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci in adult inpatients in a university teaching hospital in the UK","volume":"100","author":"Wilson","year":"2018","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.coph.2021.11.003_bib64","article-title":"Oral vancomycin, ursodeoxycholic acid or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","author":"Deneau","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib66","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/apt.14201","article-title":"Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection","volume":"46","author":"Quraishi","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib67","first-page":"CD012774","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"11","author":"Imdad","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.11.003_bib68","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib69","first-page":"179","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.coph.2021.11.003_bib70","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib71","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of \u03b14 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2016.01.001","article-title":"Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity","volume":"68","author":"Trivedi","year":"2016","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.coph.2021.11.003_bib73","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.11.003_bib74","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.gastro.2018.11.035","article-title":"Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis","volume":"156","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.11.003_bib76","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib77","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI73722","article-title":"Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis","volume":"125","author":"Weston","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2021.11.003_bib78","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A\u00a0double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib79","first-page":"2295","article-title":"Effects of tumor necrosis factor Antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.coph.2021.11.003_bib80","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib81","first-page":"1860","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.coph.2021.11.003_bib82","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/apt.14828","article-title":"The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis","volume":"48","author":"Trivedi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.11.003_bib83","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1016\/j.bmcl.2005.07.053","article-title":"SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors","volume":"15","author":"Leban","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coph.2021.11.003_bib84","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.crohns.2012.09.016","article-title":"Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study","volume":"7","author":"Herrlinger","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.coph.2021.11.003_bib85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/bmb\/ldaa035","article-title":"Cellular therapies for the treatment of immune-mediated GI and liver disease","volume":"136","author":"Khan","year":"2020","journal-title":"Br Med Bull"},{"key":"10.1016\/j.coph.2021.11.003_bib86","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/hep.30542","article-title":"Amelioration of ductular reaction by stem cell derived extracellular vesicles in MDR2 knockout mice via lethal-7 microRNA","volume":"69","author":"McDaniel","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.11.003_bib87","doi-asserted-by":"crossref","first-page":"8874","DOI":"10.3390\/ijms21228874","article-title":"Administration of human MSC-derived extracellular vesicles for the treatment of primary sclerosing cholangitis: preclinical data in MDR2 knockout mice","volume":"21","author":"Angioni","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2021.11.003_bib88","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.510300101","article-title":"Primary sclerosing cholangitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coph.2021.11.003_bib89","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.gastro.2003.07.011","article-title":"Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community","volume":"125","author":"Bambha","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib90","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, sex, and inflammatory bowel disease phenotype Associate with course of primary sclerosing cholangitis","volume":"152","author":"Weism\u00fcller","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib91","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib92","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.11.003_bib93","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib94","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib96","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.51.4.562","article-title":"Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population","volume":"51","author":"Ponsioen","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.11.003_bib97","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.11.003_bib98","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation","volume":"37","author":"Boberg","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib99","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2021.11.003_bib100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.11.003_bib101","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study","volume":"5","author":"Eksteen","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.coph.2021.11.003_bib102","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coph.2021.11.003_bib103","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/MCG.0000000000000591","article-title":"Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: a human pilot study","volume":"51","author":"Assis","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:56:47Z","timestamp":1761461807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221001636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":102,"alternative-id":["S1471489221001636"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.11.003","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging drugs for the treatment of primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}